Open Access

Circulating methylated HOXA9 tumor DNA as a biomarker for mortality in recurrent breast cancer: An exploratory study

  • Authors:
    • Stine Bakkensen Bruun
    • Rikke Fredslund Andersen
    • Jonna Skov Madsen
    • Torben Frøstrup Hansen
    • Tomasz Piotr Tabor
    • Troels Bechmann
    • Ina Mathilde Kjær
  • View Affiliations

  • Published online on: October 2, 2024     https://doi.org/10.3892/ol.2024.14714
  • Article Number: 581
  • Copyright: © Bakkensen Bruun et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Methylated homeobox A9 (meth‑HOXA9) circulating tumor DNA may be a relevant biomarker in breast cancer, although its clinical significance remains unknown. The present exploratory study aimed to investigate the association between meth‑HOXA9 and mortality in patients with recurrent breast cancer. The cohort study enrolled 51 patients with breast cancer recurrence from the Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark (Vejle, Denmark). Tissue samples from primary surgery and biopsies, and plasma samples obtained at the time of recurrence were analyzed for meth‑HOXA9 using a methylation‑specific droplet digital polymerase chain reaction. Using Cox regression, hazard ratios (HRs) for mortality with 95% confidence intervals (CIs) comparing patients with detectable and undetectable meth‑HOXA9 in both tumor tissue and plasma were estimated. Among the 50 patients with data on tumor tissue meth‑HOXA9, there was no association between meth‑HOXA9 in the primary tumor and mortality (HR 1.09, 95% CI 0.47‑2.52). A total of 34 patients had data on plasma meth‑HOXA9 at the time of recurrence. Detectable plasma meth‑HOXA9 was associated with higher mortality (HR 3.95, 95% CI 1.50‑10.37). Among the 20 patients with data on both plasma and metastatic tissue meth‑HOXA9, meth‑HOXA9 was detectable in 90% of metastases and 65% of plasma samples. In conclusion, detectable plasma meth‑HOXA9 was significantly associated with higher mortality in recurrent breast cancer; therefore, plasma meth‑HOXA9 may prove useful as a prognostic marker in patients with breast cancer.
View Figures
View References

Related Articles

Journal Cover

December-2024
Volume 28 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bakkensen Bruun S, Fredslund Andersen R, Skov Madsen J, Frøstrup Hansen T, Tabor TP, Bechmann T and Kjær IM: Circulating methylated <em>HOXA9</em> tumor DNA as a biomarker for mortality in recurrent breast cancer: An exploratory study. Oncol Lett 28: 581, 2024.
APA
Bakkensen Bruun, S., Fredslund Andersen, R., Skov Madsen, J., Frøstrup Hansen, T., Tabor, T.P., Bechmann, T., & Kjær, I.M. (2024). Circulating methylated <em>HOXA9</em> tumor DNA as a biomarker for mortality in recurrent breast cancer: An exploratory study. Oncology Letters, 28, 581. https://doi.org/10.3892/ol.2024.14714
MLA
Bakkensen Bruun, S., Fredslund Andersen, R., Skov Madsen, J., Frøstrup Hansen, T., Tabor, T. P., Bechmann, T., Kjær, I. M."Circulating methylated <em>HOXA9</em> tumor DNA as a biomarker for mortality in recurrent breast cancer: An exploratory study". Oncology Letters 28.6 (2024): 581.
Chicago
Bakkensen Bruun, S., Fredslund Andersen, R., Skov Madsen, J., Frøstrup Hansen, T., Tabor, T. P., Bechmann, T., Kjær, I. M."Circulating methylated <em>HOXA9</em> tumor DNA as a biomarker for mortality in recurrent breast cancer: An exploratory study". Oncology Letters 28, no. 6 (2024): 581. https://doi.org/10.3892/ol.2024.14714